These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 19152406)
21. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo. Rubin J; Fan X; Rahnert J; Sen B; Hsieh CL; Murphy TC; Nanes MS; Horton LG; Beamer WG; Rosen CJ Prostate; 2006 Jun; 66(8):789-800. PubMed ID: 16482567 [TBL] [Abstract][Full Text] [Related]
22. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Bauskin AR; Brown DA; Junankar S; Rasiah KK; Eggleton S; Hunter M; Liu T; Smith D; Kuffner T; Pankhurst GJ; Johnen H; Russell PJ; Barret W; Stricker PD; Grygiel JJ; Kench JG; Henshall SM; Sutherland RL; Breit SN Cancer Res; 2005 Mar; 65(6):2330-6. PubMed ID: 15781647 [TBL] [Abstract][Full Text] [Related]
25. Canine prostate stimulates osteoblast function using the endothelin receptors. LeRoy BE; Sellers RS; Rosol TJ Prostate; 2004 May; 59(2):148-56. PubMed ID: 15042615 [TBL] [Abstract][Full Text] [Related]
26. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Liu T; Bauskin AR; Zaunders J; Brown DA; Pankhurst S; Russell PJ; Breit SN Cancer Res; 2003 Aug; 63(16):5034-40. PubMed ID: 12941831 [TBL] [Abstract][Full Text] [Related]
28. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634 [TBL] [Abstract][Full Text] [Related]
29. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Yonou H; Ochiai A; Goya M; Kanomata N; Hokama S; Morozumi M; Sugaya K; Hatano T; Ogawa Y Prostate; 2004 Mar; 58(4):406-13. PubMed ID: 14968441 [TBL] [Abstract][Full Text] [Related]
30. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Schwaninger R; Rentsch CA; Wetterwald A; van der Horst G; van Bezooijen RL; van der Pluijm G; Löwik CW; Ackermann K; Pyerin W; Hamdy FC; Thalmann GN; Cecchini MG Am J Pathol; 2007 Jan; 170(1):160-75. PubMed ID: 17200191 [TBL] [Abstract][Full Text] [Related]
31. Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Izbicka E; Dunstan C; Esparza J; Jacobs C; Sabatini M; Mundy GR Cancer Res; 1996 Feb; 56(3):633-6. PubMed ID: 8564983 [TBL] [Abstract][Full Text] [Related]
32. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Keller ET; Brown J J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763 [TBL] [Abstract][Full Text] [Related]
33. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Ilvesaro JM; Merrell MA; Swain TM; Davidson J; Zayzafoon M; Harris KW; Selander KS Prostate; 2007 May; 67(7):774-81. PubMed ID: 17373717 [TBL] [Abstract][Full Text] [Related]
34. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Bellahcène A; Bachelier R; Detry C; Lidereau R; Clézardin P; Castronovo V Breast Cancer Res Treat; 2007 Jan; 101(2):135-48. PubMed ID: 17028989 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel. Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129 [TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Guise TA; Chirgwin JM Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S32-8. PubMed ID: 14600590 [TBL] [Abstract][Full Text] [Related]
37. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Russell MR; Jamieson WL; Dolloff NG; Fatatis A Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002 [TBL] [Abstract][Full Text] [Related]
38. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052 [TBL] [Abstract][Full Text] [Related]
39. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression. Kuo PT; Lin TP; Liu LC; Huang CH; Lin JK; Kao JY; Way TD J Agric Food Chem; 2009 Apr; 57(8):3331-9. PubMed ID: 19320436 [TBL] [Abstract][Full Text] [Related]
40. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]